echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Announcement of the State Food and Drug Administration on the issuance of 3 supplementary inspection methods including the supplementary inspection method for auramine O inspection items in Fuke Tiaojing Tablets (No. 15 of 2020

    Announcement of the State Food and Drug Administration on the issuance of 3 supplementary inspection methods including the supplementary inspection method for auramine O inspection items in Fuke Tiaojing Tablets (No. 15 of 2020

    • Last Update: 2021-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the relevant provisions of the "Drug Administration Law of the People's Republic of China" and its implementation regulations, "Supplementary Inspection Method for Auramine O Inspection Items in Fuke Tiaojing Tablets", "Supplementary Inspection Methods for Inspection Items of Bovine Source Components in Lvjiao Buxue Granules" and "Announcement The Supplementary Inspection Method for the Inspection Items of Rice-derived Components in Lifei Pills (Shui Mi Pills) and Jiu Wei Qiang Huo Pills (Shui Pills)" is hereby released after the approval of the State Drug Administration
    .

    Hereby announce
    .


    Attachment: 1.
    Supplementary inspection method for auramine O inspection items in Fuke Tiaojing Tablets

    2.
    Supplementary inspection method for the check items of cowhide source components in donkey glue Buxue granules

    3.
    Supplementary inspection methods for inspection items of rice-derived components in Tongxuan Lifei Pills (Shui Mi Pills) and Jiu Wei Qiang Huo Pills (Water Pills)


    State Food and Drug Administration

    December 30, 2020





    Announcement No.
    151 of 2020 of the National Medical Products Administration Annex 1.
    doc

    Announcement No.
    151 of 2020, Annex 2 of the National Medical Products Administration.
    doc

    Attachment 3.
    doc of Announcement No.


    151 of 2020 of the National Medical Products Administration



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.